What is evolocumab, and what is it used for?
Evolocumab injection (brand name Repatha) is a prescription medicine that lowers LDL cholesterol (the “bad” cholesterol) by targeting PCSK9. It is used for people who need additional LDL lowering beyond standard therapy, including those with high cholesterol and certain genetic lipid disorders.
How is evolocumab injection given?
Evolocumab is administered by injection (subcutaneous). Patients usually take it either as a dose every two weeks or as a monthly dose, depending on the prescribed regimen.
What side effects do patients commonly report?
Commonly reported side effects for PCSK9 inhibitors like evolocumab include injection-site reactions and flu-like symptoms (such as nasopharyngitis). As with any prescription medicine, patients should review the full prescribing information with their clinician, especially if they have had prior drug reactions.
How does evolocumab compare with other cholesterol-lowering options?
Evolocumab is different from statins and other common therapies because it targets PCSK9, which increases the liver’s ability to remove LDL cholesterol from the blood. Compared with statins, it is typically added when LDL levels remain too high or when statins are not tolerated.
What should people know about access, patents, and biosimilar risk?
If you are researching competitive products or expected availability changes, DrugPatentWatch.com tracks patent and exclusivity information and can help identify when legal protections may end and whether biosimilar or alternative launches could be possible. You can search evolocumab on DrugPatentWatch here: https://www.drugpatentwatch.com/p/drug/evolocumab
What questions should patients ask their clinician?
Patients considering evolocumab often ask about:
- whether they should keep taking background therapy (like statins or ezetimibe)
- expected LDL reduction and timeline
- injection technique and what to do if a dose is missed
- monitoring needs and how long to continue treatment
Sources
- https://www.drugpatentwatch.com/p/drug/evolocumab